Kodiak Sciences: Clinical Redemption Is Turning Into Platform Leverage

Kodiak Sciences (KOD) is transitioning from past clinical disappointments to a maturing retina platform with multiple near-term catalysts. Recent GLOW2 Phase 3 success for Zenkuda in diabetic retinopathy and upcoming pivotal data for Zenkuda, KSI-501, and KSI-101 underpin a bullish outlook. KOD's current $169.5M cash position supports near-term catalysts, but additional capital will be needed for commercialization and late-stage development.

Seeking Alpha • Jun 16, 2026

Kodiak Stock Rises 35% in 3 Months: Here's What You Need to Know

KOD surges on positive phase III Zenkuda data, accelerated regulatory plans, advancing late-stage programs and a strengthened balance sheet.

Zacks Investment Research • Jun 4, 2026

Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference

PALO ALTO, Calif., May 28, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that Victor Perlroth, M.D.

PRNewsWire • May 28, 2026

Kodiak's Q1 Loss Wider Than Expected, Pipeline Development in Focus

KOD posts a wider Q1 loss as research & development spending rises, while positive phase III Zenkuda data accelerate the regulatory plans.

Zacks Investment Research • May 8, 2026

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results

PALO ALTO, Calif., May 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended March 31, 2026.

PRNewsWire • May 7, 2026

Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences

Clinical results of KSI-101 in macular edema secondary to inflammation (MESI) from a tertiary care uveitis practice demonstrate outcomes consistent with results from the U.S. Phase 1b APEX study, supporting continued global development and expansion of the Phase 3 PEAK and PINNACLE program into Asia. Ongoing advancement of bispecific therapies in geographic atrophy and ocular inflammatory disease; preclinical data continue to support a multi-target approach to address limitations of current single-target therapies.

PRNewsWire • May 1, 2026

Kodiak Sciences (KOD) Up 2% Since Last Earnings Report: Can It Continue?

Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Apr 30, 2026

Russell 2000 Rips To Record High — Here Are The Top Small Cap Gainers

The small-cap Russell 2000 punched through to an intraday record high on Friday, capping a furious 13-day rally that marks the index's best run since 2020 and signaling that gains are finally broadening beyond the mega-cap tech leaders.

Benzinga • Apr 17, 2026

Kodiak Q4 Loss Wider Than Expected, Pipeline Development in Focus

KOD posts wider Q4 loss. However, its pipeline advances, with strong phase III data for Zenkuda driving accelerated regulatory plans.

Zacks Investment Research • Apr 1, 2026

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

PALO ALTO, Calif., March 31, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2025.

PRNewsWire • Mar 31, 2026